Related Experiment Video
Updated: Jan 16, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
[Emerging treatment approaches targeting the molecular pathogenesis of myelofibrosis]
1Department of Hematology and Rheumatology, Kindai University Faculty of Medicine.
Abstract:
Myeloproliferative neoplasms (MPNs) are a group of disorders characterized by the activation of the JAK/STAT signaling pathway at the level of hematopoietic stem cells. In one subtype, myelofibrosis (MF), JAK inhibitors have become the standard therapy for high-risk patients who are not eligible for hematopoietic stem cell transplantation. While current JAK inhibitors can alleviate disease-related symptoms, they have not yet been shown to modify the disease course or achieve a cure. In contrast, a watchful waiting approach is generally adopted for asymptomatic low-risk MF. Recently, advances in our understanding of the molecular pathogenesis of MPNs have led to the development of novel therapeutic strategies that could alter disease progression in addition to managing symptoms and complications. This article reviews the latest basic research on the pathogenesis and progression of MPNs, and provides an overview of current and emerging treatment strategies, with a particular focus on MF.
Insights
Myeloproliferative neoplasms (MPNs), particularly myelofibrosis (MF), involve JAK/STAT pathway activation. Novel therapies aim to alter disease progression beyond symptom management for MF patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myeloproliferative neoplasms (MPNs) are stem cell disorders driven by JAK/STAT pathway activation.
- Myelofibrosis (MF) is a subtype where JAK inhibitors are standard for high-risk patients awaiting transplantation.
- Current JAK inhibitors manage symptoms but do not alter disease course or offer a cure.
Purpose of the Study:
- To review recent basic research on MPN pathogenesis and progression.
- To provide an overview of current and emerging treatments for MPNs, focusing on MF.
- To highlight novel therapeutic strategies targeting disease modification.
Main Methods:
- Literature review of basic science research.
- Analysis of current clinical data on JAK inhibitors in MF.
- Exploration of emerging therapeutic strategies for MPNs.
Main Results:
- JAK/STAT pathway activation is central to MPN pathogenesis.
- JAK inhibitors offer symptomatic relief in MF but lack curative potential.
- Advances in understanding MPN molecular biology are driving new therapeutic approaches.
Conclusions:
- Novel therapies hold promise for altering MPN disease progression.
- Targeting molecular pathways offers potential for improved outcomes in MF.
- Continued research is crucial for developing curative strategies for MPNs.
